SecBot SecBot
8-K ·Filed May 7, 2026

PVLA

PALVELLA THERAPEUTICS, INC.
BEARISH
Impact 6/10
Horizonweeks Processed6mo ago SEC0001193125-26-210605
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The earnings miss may pressure PVLA shares near-term, but the strong cash runway and upcoming NDA submission provide a catalyst. Watch for pre-NDA meeting outcomes and pipeline milestones in 2H 2026.

DirectionBearish
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$113.26
T+0 close · May 7, 2026 · via day close
Latest settled
+24.30%
T+60 · $140.78
Vs SPY
+20.46%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $113.26entry
  2. T+1 · 6mo ago +7.09%α +6.26% · $121.29
  3. T+5 · 6mo ago +6.45%α +4.95% · $120.57
  4. T+20 · 6mo ago +1.91%α −1.23% · $115.42
  5. T+60 · 4mo ago +24.30%α +20.46% · $140.78
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Palvella Therapeutics reported Q1 2026 EPS of -$1.20, missing consensus of -$0.93 by 29%, as R&D and G&A expenses rose sharply. Despite the miss, the company highlighted strong cash of $261.9M and reiterated NDA submission for QTORIN rapamycin in microcystic LMs in 2H 2026, with potential approval and launch in 1H 2027.

Key Financial Metrics

EPS
−$1.20
est −$0.93 · -29.0%
Revenue
$0.00
est $0.00
Rating
miss

Key Facts

  • Q1 2026 EPS of -$1.20 missed consensus of -$0.93 (29% miss)
  • Net loss of $15.8M vs $8.2M in Q1 2025, driven by higher R&D and G&A costs
  • Cash, cash equivalents and short-term investments of $261.9M as of March 31, 2026
  • NDA submission for QTORIN rapamycin in microcystic LMs on track for 2H 2026
  • Phase 3 SELVA study met all primary and secondary endpoints; pre-NDA meeting granted

Financial Impact

EPS miss of $0.27 per share

epsnet_loss

Risk Factors

  • EPS miss may lead to negative sentiment and near-term selling
  • Clinical and regulatory risks ahead of NDA submission and approval

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-210605
Document: pvla-20260507.htm0001193125-26-210605
Document: pvla-ex99_2.htm0001193125-26-210605
Document: 0001193125-26-210605-index-headers.html0001193125-26-210605
Document: 0001193125-26-210605-index.html0001193125-26-210605
Document: 0001193125-26-210605.txt0001193125-26-210605
8-K Data (Synthetic)0001193125-26-210605

US Market Status

Market Closed · Opens in 6h 3m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026